Amplia CEO and MD Dr Chris Burns commented: “The recruitment of our 26th patient is an important
milestone for the Company. With 26 patients enrolled, and based on experience to date, we believe
that the outcome from the interim analysis will be reported around the beginning of Q4 2024. Imaging
data for the first patients from this cohort is now being collated and efficacy signals to date mirror the
positive data previously reported from the Phase 1b stage of the trial.”
Time to place your bets... As cheap as chips atm.
No advices here as It is a very risky bet with a binary outcome !
Ann: First 26 Patients recruited in Phase 2A ACCENT Trial, page-2
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
24.0¢ |
Change
0.005(2.13%) |
Mkt cap ! $116.7M | |||
| Open | High | Low | Value | Volume |
| 24.0¢ | 24.5¢ | 22.5¢ | $2.020M | 8.588M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 230225 | 23.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 24.0¢ | 778184 | 1 |
View Market Depth
| Last trade - 16.10pm 30/07/2025 (20 minute delay) ? |
| ATX (ASX) Chart |